<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Neurol</journal-id><journal-id journal-id-type="publisher-id">IJNL</journal-id><journal-title-group><journal-title>Iranian Journal of Neurology</journal-title></journal-title-group><issn pub-type="ppub">2008-384X</issn><issn pub-type="epub">2252-0058</issn><publisher><publisher-name>Tehran University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29114367</article-id><article-id pub-id-type="pmc">5673984</article-id><article-id pub-id-type="publisher-id">IJNL-16-125</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The comparison of anti-seizure and tocolytic effects of phenytoin and magnesium sulphate in the treatment of eclampsia and preeclampsia: A randomised clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khooshideh</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ghaffarpour</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bitarafan</surname><given-names>Sama</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Department of Obstetrics and Gynecology, School of Medicine, Arash Hospital, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="aff2">
<label>2</label>Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran</aff><author-notes><corresp id="cor">Corresponding Author: Sama Bitarafan<email>Email: bitarafan@sina.tums.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><day>6</day><month>7</month><year>2017</year></pub-date><volume>16</volume><issue>3</issue><fpage>125</fpage><lpage>129</lpage><history><date date-type="received"><day>22</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Iranian Neurological Association, and Tehran University of Medical Sciences</copyright-statement><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<bold>Background:</bold> To date, magnesium sulphate (MgSO<sub>4</sub>) is the treatment of choice for prevention of seizure in eclampsia and preeclampsia. However, there are some limitations in the administration of MgSO<sub>4</sub> due to its tocolytic effects. The aim of this study was to compare the anticonvulsant and tocolytic effects of MgSO<sub>4 </sub>and another drug, phenytoin, in patients with eclampsia and preeclampsia.</p><p>
<bold>Methods:</bold> This clinical trial was conducted on pregnant women hospitalised with eclampsia or preeclampsia, during 2014&#x02013;2016. The subjects were randomly assigned to two treatment groups using blocking method based on disease (eclampsia or mild and severe preeclampsia). One group received MgSO<sub>4</sub> (group M) and another group received phenytoin (group P) as treatment. Each group consisted of 110 and 65 women with mild and severe preeclampsia, respectively (subgroup A), and 25 women with eclampsia (subgroup B). Duration of labor, the number of cesarean sections, convulsions and Apgar scores of infants were compared between the two groups and were considered as treatment outcomes.</p><p>
<bold>Results:</bold> Convulsion rate was significantly lower with MgSO<sub>4</sub> than phenytoin (P = 0.001). No seizure occurred in patients with mild preeclampsia in group P. Duration of stage one of labor (P &#x0003c; 0.001) and the number of cesarean sections (P = 0.040) were significantly higher in group M. However, one-minute Apgar scores for newborns were higher in women treated with MgSO<sub>4</sub> compared to that of phenytoin (P = 0.001). Five-minute Apgar was not significantly different.</p><p>
<bold>Conclusion:</bold> Although MgSO<sub>4</sub> is more effective than phenytoin for prevention of convulsion in eclampsia and severe preeclampsia, phenytoin may be considered for treatment of special conditions such as mild preeclampsia. Due to the tocolytic effects of MgSO<sub>4</sub> on increasing the duration of labor, the increased risk of cesarean section and the potential for toxicity, physicians should critically consider the best drug according to the condition of the patient.</p></abstract><kwd-group><title>Key Words</title><kwd>Phenytoin</kwd><kwd>Magnesium Sulphate</kwd><kwd>Cesarean Section</kwd><kwd>Eclampsia</kwd><kwd>Preeclampsia</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Preeclampsia is a prevalent multisystem disorder. It is associated with systolic blood pressure of &#x02265; 140 mmHg and/or diastolic blood pressure of &#x02265; 90 mmHg after 20 weeks of gestation and occurrence of proteinuria in previously normotensive patients. Severe preeclampsia can damage several organs such as liver, kidneys, clotting system and brain.<sup><xref rid="B1" ref-type="bibr">1</xref></sup><sup>-</sup><sup><xref rid="B3" ref-type="bibr">3</xref></sup> Preeclampsia and eclampsia are the second largest cause of maternal morbidity.<sup><xref rid="B4" ref-type="bibr">4</xref></sup><sup>-</sup><sup><xref rid="B6" ref-type="bibr">6</xref></sup></p><p>Severe preeclampsia without anti-seizure prophylaxis transforms to eclampsia and new-onset generalised seizures occur in eclamptic women.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Women with eclampsia should receive anticonvulsant therapy but there is controversy about this choice.<sup><xref rid="B8" ref-type="bibr">8</xref></sup><sup>-</sup><sup><xref rid="B10" ref-type="bibr">10</xref></sup> Anticonvulsant drugs generally used as prophylaxis are diazepam, phenytoin and MgSO<sub>4,</sub><sup><xref rid="B7" ref-type="bibr">7</xref></sup><sup>,</sup><sup><xref rid="B10" ref-type="bibr">10</xref></sup> but many studies reported that MgSO<sub>4</sub> is the first choice of therapy.<sup><xref rid="B11" ref-type="bibr">11</xref></sup><sup>-</sup><sup><xref rid="B13" ref-type="bibr">13</xref></sup>
</p><p>Convulsion may occur due to interference in the regulation of cerebral circulation, dysfunction of endothelium and brain edema.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> MgSO<sub>4</sub> stimulates the release of prostacyclin from endothelium and acts as a vasodilator, reducing systemic blood pressure and protecting from cerebral edema.<sup><xref rid="B14" ref-type="bibr">14</xref></sup><sup>-</sup><sup><xref rid="B16" ref-type="bibr">16</xref></sup></p><p>Advantages of MgSO<sub>4</sub> therapy are rapid onset of action, easily available antidote (calcium gluconate), lack of sedation and low cost. On the other side, some side effects of MgSO<sub>4</sub> can occur in patients such as painful intramuscular administration, flushing and warmth, nausea, vomiting, headache and muscle weakness. Also, dyspnea, chest pain, pulmonary edema, cardiac arrest and respiratory depression due to magnesium toxicity may be seen in MgSO<sub>4</sub> therapy.<sup><xref rid="B17" ref-type="bibr">17</xref></sup> The tocolytic activity of MgSO<sub>4</sub> can increase the duration of labor, the number of cesarean section, and post-partum hemorrhage.<sup><xref rid="B9" ref-type="bibr">9</xref></sup><sup>,</sup><sup><xref rid="B18" ref-type="bibr">18</xref></sup><sup>,</sup><sup><xref rid="B19" ref-type="bibr">19</xref></sup></p><p>However, some traditional anticonvulsant drugs such as phenytoin are useful as alternatives.<sup><xref rid="B8" ref-type="bibr">8</xref></sup><sup>,</sup><sup><xref rid="B9" ref-type="bibr">9</xref></sup> Phenytoin crosses the blood-brain barrier rapidly. Side effects of phenytoin include dysrhythmia, hypotension fever, skin rash around the eyes and allergy.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> The aim of this study was to compare the effects of MgSO<sub>4</sub> and phenytoin in terms of method and duration of labor and the rate of seizure in patients with eclampsia and preeclampsia.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>After approval from the ethics committee, the present randomised clinical trial study was conducted on 400 pregnant women admitted with eclampsia, mild and severe preeclampsia to Arash Hospital in Tehran, Iran, during the time period 2014-2016 (clinical trial number: IRCT2016120311020N7). </p><p>Primiparous women with mild and severe preeclampsia and eclampsia and &#x02265; 34-week gestational age were included in the trial. Patients with heart disease, multifetal pregnancy, smokers, drug users and women with hypersensitivity to MgSO<sub>4</sub> or phenytoin were excluded. According to the mentioned inclusion criteria, the patients were chosen with random blocking method based on the disease (eclampsia or mild and severe preeclampsia) and were assigned to one of the two treatment groups. One group received MgSO<sub>4</sub> (group M) and another group received phenytoin (group P) as treatment. In each group, 110 women with mild and 65 women with severe preeclampsia (subgroup A), and 25 women with eclampsia (subgroup B) were included (<xref ref-type="fig" rid="F1">Figure 1</xref>). </p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Diagram of the study</p></caption><graphic xlink:href="IJNL-16-125-g001"/></fig><p>Study outcomes, duration of labor, the number of cesarean sections, the number of convulsion events and Apgar scores of infants were compared between groups.</p><p>Mild preeclampsia was defined as systolic blood pressure of &#x02265; 140 mmHg and/or diastolic blood pressure of &#x02265; 90 mmHg after 20 weeks of gestation and proteinuria. Severe preeclampsia was defined as systolic blood pressure of &#x02265; 160 mmHg and/or diastolic blood pressure of &#x02265; 110 mmHg or when patients with preeclampsia had organ damage such as in liver, kidneys, clotting system, or brain. Eclampsia referred to the occurrence of new-onset tonic-clonic seizures or coma in a patient with preeclampsia. </p><p>Group M received the loading dose of 4 g 20% MgSO<sub>4</sub> in 100 ml of lactated Ringer's solution intravenously over 20 min, followed by 2 g/hour IV infusion. Patients were monitored every 4 hours regarding the following parameters: presentation of patellar reflex, urine output &#x0003e; 100 ml/4 hours or &#x0003e; 25 ml/hour, and respiratory rate &#x0003e; 12/min. In group P loading dose of 20 mg/kg body weight (maximum 1000 mg) of phenytoin in 100 ml of lactated Ringer's solution was given intravenously slowly over 20 minutes. A maintenance dose of 500 mg was given orally after 10 hours. Therapy was continued for 24 hours post-partum or after the last convulsion following delivery.</p><p>The number of convulsions was recorded every four hours and all other laboratory data were recorded every six hours. Complications such as acute renal failure, cerebrovascular accident, and hepatic failure, were also recorded if present. Apgar scores of the fetus at one and five minutes were noted. Duration of labor and the type of delivery were also recorded.</p><p>All data analyses were conducted using SPSS for windows (version 16, SPSS Inc., Chicago, IL, USA). Descriptive statistics for continuous variables were presented as mean &#x000b1; standard deviation and for categorical variables as numbers (percentage). The baseline characteristics of the two groups were compared using an independent t-test for continuous variables and the chi-square test for categorical variables. Moreover, the convulsions were compared between the groups using chi-square test. All statistical tests were two-sided and the level of statistical significance cut-off was set at 0.05. All analyses were performed on an intent-to-treat basis. The conduct and analysis of the trial strictly adhered to the 2010 CONSORT guidelines.</p></sec><sec sec-type="results"><title>Results</title><p>The mean age of patients in the group M was 27.4 &#x000b1; 5.9 and in the group P was 27.5 &#x000b1; 5.7. In the group M, the mean body mass index (BMI) was 24.38 &#x000b1; 2.72 and in group P it was 24.68 &#x000b1; 2.74. The differences between the two groups in mean age (P = 0.920) (<xref ref-type="table" rid="T1">Table 1</xref>) and mean BMI (P = 0.270) (<xref ref-type="table" rid="T1">Table 1</xref>) were not significant. Also, there was no statistically significant difference between group M (36.25 &#x000b1; 1.18) and group P (36.45 &#x000b1; 1.07) in mean gestational age (P = 0.120) (<xref ref-type="table" rid="T1">Table 1</xref>). </p><p>The number of convulsion attacks in patients allocated in MgSO<sub>4</sub> group was 0, and in patients treated with phenytoin was 10 (seven convulsions in patients with severe preeclampsia and three convulsions in patients with eclampsia). MgSO<sub>4</sub> was significantly more efficient than phenytoin for convulsion prevention (P = 0.001) (<xref ref-type="table" rid="T2">Table 2</xref>). </p><p>Duration of stage 1 of labor was significantly longer in group M (294.4 &#x000b1; 103.2 min) compared to group P (258.80 &#x000b1; 101.01 min, P &#x0003c; 0.001) (<xref ref-type="table" rid="T2">Table 2</xref>). </p><p>Duration of stage 2 of labor was also longer in group M (48.18 &#x000b1; 16.05 min) compared to group P (46.21 &#x000b1; 15.20 min), but the differences were not statistically significant (P = 0.200) (<xref ref-type="table" rid="T2">Table 2</xref>). The rate of cesarean section was significantly greater in group M (45%) compared to group P (35%) (P = 0.040). MgSO<sub>4</sub> induced longer labor and increased the rate of cesarean sections in comparison to phenytoin. </p><p>There was a statistically significant difference in one-minute Apgar score between group M (8.57 &#x000b1; 1.50) and group P (8.06 &#x000b1; 1.66) (P = 0.001) (<xref ref-type="table" rid="T2">Table 2</xref>) but there was no significant difference in the five-minutes Apgar score (P = 0.340) (<xref ref-type="table" rid="T2">Table 2</xref>). The one-minute Apgar score for newborns was higher in group M but finally, it was same in both groups.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th style=" color:#231F20;" align="left" rowspan="1" colspan="1">
<bold>Baseline demographics</bold>
</th><th style=" color:#231F20;" align="center" rowspan="1" colspan="1">
<bold>Group M (n = 200)</bold>
</th><th style=" color:#231F20;" align="center" rowspan="1" colspan="1">
<bold>Group P (n = 200)</bold>
</th><th style=" color:#231F20;" align="center" rowspan="1" colspan="1">
<bold>P</bold>
</th></tr></thead><tbody><tr><td style=" color:#231F20;" align="left" rowspan="1" colspan="1">Age (years) (mean &#x000b1; SD)</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">27.40 &#x000b1; 5.90</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">27.50 &#x000b1; 5.70</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">0.924</td></tr><tr><td style=" color:#231F20;" align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>) (mean &#x000b1; SD)</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">24.38 &#x000b1; 2.72</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">24.68 &#x000b1; 2.74</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">0.273</td></tr><tr><td style=" color:#231F20;" align="left" rowspan="1" colspan="1">Gestational age (weeks) (mean &#x000b1; SD)</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">36.25 &#x000b1; 1.18</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">36.45 &#x000b1; 1.07</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">0.120</td></tr></tbody></table><table-wrap-foot><p>SD: Standard deviation </p></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Primary and secondary outcomes of study</p></caption><table frame="hsides" rules="groups"><thead><tr><th style=" color:#231F20;" align="left" rowspan="1" colspan="1">
<bold>Outcomes</bold>
</th><th style=" color:#231F20;" align="center" rowspan="1" colspan="1">
<bold>Group M (n = 200)</bold>
</th><th style=" color:#231F20;" align="center" rowspan="1" colspan="1">
<bold>Group P (n = 200)</bold>
</th><th style=" color:#231F20;" align="center" rowspan="1" colspan="1">
<bold>P</bold>
</th></tr></thead><tbody><tr><td style=" color:#231F20;" align="left" rowspan="1" colspan="1">Apgar 1 min (mean &#x000b1; SD)</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">8.57 &#x000b1; 1.50</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">8.06 &#x000b1; 1.66</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td style=" color:#231F20;" align="left" rowspan="1" colspan="1">Apgar 5 min (mean &#x000b1; SD)</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">9.88 &#x000b1; 0.40</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">9.86 &#x000b1; 0.43</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">0.340</td></tr><tr><td style=" color:#231F20;" align="left" rowspan="1" colspan="1">Duration of stage 1 of labor (min) (mean &#x000b1; SD)</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">294.40 &#x000b1; 103.2<underline>0</underline></td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">258.80 &#x000b1; 101.01</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td style=" color:#231F20;" align="left" rowspan="1" colspan="1">Duration of stage 2 of labor (min) (mean &#x000b1; SD)</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">48.18 &#x000b1; 16.05</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">46.21 &#x000b1; 15.20</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">0.200</td></tr><tr><td style=" color:#231F20;" align="left" rowspan="1" colspan="1">Rate of cesarean section (%)</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">45</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">35</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">0.040</td></tr><tr><td style=" color:#231F20;" align="left" rowspan="1" colspan="1">Convulsion in patients with mild preeclampsia (n)</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">0</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">0</td><td style=" color:#231F20;" align="center" rowspan="3" colspan="1">0.001</td></tr><tr><td style=" color:#231F20;" align="left" rowspan="1" colspan="1">Convulsion in patients with severe preeclampsia (n)</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">0</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">7</td></tr><tr><td style=" color:#231F20;" align="left" rowspan="1" colspan="1">Convulsion in patients with eclampsia (n)</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">0</td><td style=" color:#231F20;" align="center" rowspan="1" colspan="1">3</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>In the present study, seizures were observed in 10 patients in phenytoin group (7 patients in severe preeclampsia subgroup and 3 patients in eclampsia subgroup) and no seizure occurred in MgSO<sub>4</sub> group and/or in patients with mild preeclampsia in the phenytoin group after the trial. </p><p>MgSO<sub>4</sub> is known as a better choice compared to phenytoin for prevention of seizures in patients with eclampsia and preeclampsia.<sup><xref rid="B16" ref-type="bibr">16</xref></sup><sup>,</sup><sup><xref rid="B20" ref-type="bibr">20</xref></sup> However, Slater and colleagues reported 100% treatment success in their study on 26 women with preeclampsia and eclampsia who were given phenytoin.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> Possible explanations for this inconsistency in studies may be the administration of different doses of phenytoin. In a study by Robson, et al., three women had seizures despite receiving therapeutic levels of phenytoin.<sup><xref rid="B22" ref-type="bibr">22</xref></sup> Appleton, et al. explained that therapeutic threshold of phenytoin in non-pregnant patients and pregnant women with preeclampsia may be different.<sup><xref rid="B23" ref-type="bibr">23</xref></sup></p><p>In the present study, both the rate of cesarean section and duration of labor in MgSO<sub>4</sub> group were significantly higher than phenytoin group. Our study showed that the tocolytic effects of MgSO<sub>4</sub> are considerably higher compared to that of phenytoin, but MgSO<sub>4</sub> is also more effective than phenytoin in the prevention of convulsions. </p><p>Our results are in accordance with many previous researches that reported a statistically significant increase in the duration of labor and the rate of cesarean section in patients treated with MgSO<sub>4</sub> compared to phenytoin.<sup><xref rid="B5" ref-type="bibr">5</xref></sup><sup>,</sup><sup><xref rid="B24" ref-type="bibr">24</xref></sup><sup>,</sup><sup><xref rid="B25" ref-type="bibr">25</xref></sup> In contrast, Belfort, et al. showed that MgSO<sub>4</sub> is a weak tocolytic drug and labor duration does not appear to be affected by its administration.<sup><xref rid="B26" ref-type="bibr">26</xref></sup> Moreover, some studies, reported no tocolytic effects for MgSO<sub>4</sub> in women with preeclampsia.<sup><xref rid="B18" ref-type="bibr">18</xref></sup><sup>,</sup><sup><xref rid="B27" ref-type="bibr">27</xref></sup><sup>,</sup><sup><xref rid="B28" ref-type="bibr">28</xref></sup></p><p>Phenytoin induced more rapid cervical dilation than MgSO<sub>4</sub> and did not increase the duration of labor.<sup><xref rid="B25" ref-type="bibr">25</xref></sup> Patients treated with phenytoin had significantly less postpartum hemorrhage,<sup><xref rid="B5" ref-type="bibr">5</xref></sup><sup>,</sup><sup><xref rid="B29" ref-type="bibr">29</xref></sup> and less time was required to regain consciousness compared to patients treated with MgSO<sub>4</sub>.<sup><xref rid="B5" ref-type="bibr">5</xref></sup>
</p><p>Therefore, phenytoin can decrease the need for skilled workers in the delivery room. It might be important for hospitals in the low- and middle-income countries with a high prevalence of patients with preeclampsia and eclampsia and insufficient facilities. Phenytoin can be helpful for hospitals that experience increased bed turn-over in those countries. </p><p>Because of the intensive care requirement for maternal monitoring during intravenous infusion of MgSO<sub>4</sub> or risk of toxicity, particularly where the capacity of maternal monitoring is limited, phenytoin seems to have practical implications. </p><p>The present study showed that one-minute Apgar score was lower in phenytoin group but five-minute Apgar score did not differ significantly. Roy, et al. showed that infants born in MgSO<sub>4</sub> group had higher Apgar scores compared to phenytoin group, but the results were not statistically significant.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> Phenytoin does not have a significant effect on Apgar score.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Although MgSO<sub>4 </sub>is apparently a better choice than phenytoin for the prevention of seizure in eclampsia and severe preeclampsia, phenytoin can be considered for treatment in specific conditions such as mild preeclampsia, owing to its lower risk of convulsion. Phenytoin can be practically implicated in low- and middle-income countries where the capacity for maternal monitoring is limited, considering the potential for toxicity of MgSO<sub>4</sub> when administered without intensive care. Further studies are recommended with larger sample size and different drug dosage.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors wish to thank Tehran University of Medical Sciences and Health Services that has supported the present study.</p></ack><sec><title>Conflict of Interests</title><p>The authors declare no conflict of interest in this study.</p></sec><sec><title>Notes:</title><p>
<bold>How to cite this article:</bold> Khooshideh M, Ghaffarpour M, Bitarafan S. The comparison of anti-seizure and tocolytic effects of phenytoin and magnesium sulphate in the treatment of eclampsia and preeclampsia: A randomised clinical trial. Iran J Neurol 2017; 16(3): 125-9.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heard</surname><given-names>AR</given-names></name><name><surname>Dekker</surname><given-names>GA</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name><name><surname>Jacobs</surname><given-names>DJ</given-names></name><name><surname>Vreeburg</surname><given-names>SA</given-names></name><name><surname>Priest</surname><given-names>KR</given-names></name></person-group><article-title>Hypertension during pregnancy in South Australia, Part 1: Pregnancy outcomes</article-title><source> Australian and New Zealand J Obstet Gynaecol</source><year>2004</year><volume>44</volume><issue>5</issue><fpage>404</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15387860</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danmusa</surname><given-names>S</given-names></name><name><surname>Coeytaux</surname><given-names>F</given-names></name><name><surname>Potts</surname><given-names>J</given-names></name><name><surname>Wells</surname><given-names>E</given-names></name></person-group><article-title>Scale-up of magnesium sulfate for treatment of pre-eclampsia and eclampsia in Nigeria</article-title><source> Int J Gynaecol Obstet</source><year>2016</year><volume>134</volume><issue>3</issue><fpage>233</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">27394067</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauth</surname><given-names>JC</given-names></name><name><surname>Ewell</surname><given-names>MG</given-names></name><name><surname>Levine</surname><given-names>RJ</given-names></name><name><surname>Esterlitz</surname><given-names>JR</given-names></name><name><surname>Sibai</surname><given-names>B</given-names></name><name><surname>Curet</surname><given-names>LB</given-names></name><etal/></person-group><article-title>Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group</article-title><source> Obstet Gynecol</source><year>2000</year><volume>95</volume><issue>1</issue><fpage>24</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10636496</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nwanodi</surname><given-names>OB</given-names></name></person-group><article-title>Preeclampsia-eclampsia adverse outcomes reduction: The preeclampsia-eclampsia checklist</article-title><source> Healthcare (Basel)</source><year>2016</year><volume>4</volume><issue>2</issue><fpage>E26</fpage><pub-id pub-id-type="pmid">27417614</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>J</given-names></name><name><surname>Mitra</surname><given-names>JK</given-names></name><name><surname>Pal</surname><given-names>A</given-names></name></person-group><article-title>Magnesium sulphate versus phenytoin in eclampsia - Maternal and fetal outcome - A comparative study</article-title><source> Australas Med J</source><year>2013</year><volume>6</volume><issue>9</issue><fpage>483</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">24133541</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Mir</surname><given-names>S</given-names></name><name><surname>Rizvi</surname><given-names>M</given-names></name><name><surname>Akthar</surname><given-names>S</given-names></name></person-group><article-title>Efficacy of magnesium sulphate versus phenytoin in seizure control and prophylaxis in patients of eclampsia and severe pre-eclampsia</article-title><source> JK science</source><year>2008</year><volume>10</volume><issue>4</issue><fpage>181</fpage><lpage>5</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Euser</surname><given-names>AG</given-names></name><name><surname>Cipolla</surname><given-names>MJ</given-names></name></person-group><article-title>Magnesium sulfate for the treatment of eclampsia: a brief review</article-title><source> Stroke</source><year>2009</year><volume>40</volume><issue>4</issue><fpage>1169</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">19211496</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>R</given-names></name><name><surname>Magee</surname><given-names>LA</given-names></name><name><surname>Payne</surname><given-names>B</given-names></name><name><surname>Firoz</surname><given-names>T</given-names></name><name><surname>Sawchuck</surname><given-names>D</given-names></name><name><surname>Tu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens</article-title><source> J Obstet Gynaecol Can</source><year>2014</year><volume>36</volume><issue>2</issue><fpage>154</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">24518915</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duley</surname><given-names>L</given-names></name><name><surname>Matar</surname><given-names>HE</given-names></name><name><surname>Almerie</surname><given-names>MQ</given-names></name><name><surname>Hall</surname><given-names>DR</given-names></name></person-group><article-title>Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia</article-title><source> Cochrane Database Syst Rev</source><year>2010</year><issue>8</issue><fpage>CD007388</fpage><pub-id pub-id-type="pmid">20687086</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>Q</given-names></name><name><surname>Oladapo</surname><given-names>OT</given-names></name><name><surname>Leathersich</surname><given-names>S</given-names></name><name><surname>Vogel</surname><given-names>JP</given-names></name><name><surname>Carroli</surname><given-names>G</given-names></name><name><surname>Lumbiganon</surname><given-names>P</given-names></name><etal/></person-group><article-title>Clinical practice patterns on the use of magnesium sulphate for treatment of pre-eclampsia and eclampsia: a multi-country survey</article-title><source> BJOG</source><year>2017</year><volume>124</volume><fpage>1883</fpage><lpage>1890</lpage><pub-id pub-id-type="pmid">27885772</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duley</surname><given-names>L</given-names></name><name><surname>Gulmezoglu</surname><given-names>AM</given-names></name></person-group><article-title>Magnesium sulphate versus lytic cocktail for eclampsia</article-title><source> Cochrane Database Syst Rev</source><year>2001</year><issue>1</issue><fpage>CD002960</fpage><pub-id pub-id-type="pmid">11279786</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duley</surname><given-names>L</given-names></name><name><surname>Henderson-Smart</surname><given-names>D</given-names></name></person-group><article-title>Magnesium sulphate versus diazepam for eclampsia</article-title><source> Cochrane Database Syst Rev</source><year>2003</year><issue>4</issue><fpage>CD000127</fpage><pub-id pub-id-type="pmid">14583910</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokslag</surname><given-names>A</given-names></name><name><surname>van</surname><given-names>Weissenbruch M</given-names></name><name><surname>Mol</surname><given-names>BW</given-names></name><name><surname>de</surname><given-names>Groot CJ</given-names></name></person-group><article-title>Preeclampsia; short and long-term consequences for mother and neonate</article-title><source> Early Hum Dev</source><year>2016</year><volume>102</volume><fpage>47</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">27659865</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotton</surname><given-names>DB</given-names></name><name><surname>Hallak</surname><given-names>M</given-names></name><name><surname>Janusz</surname><given-names>C</given-names></name><name><surname>Irtenkauf</surname><given-names>SM</given-names></name><name><surname>Berman</surname><given-names>RF</given-names></name></person-group><article-title>Central anticonvulsant effects of magnesium sulfate on N-methyl-D-aspartate-induced seizures</article-title><source> Am J Obstet Gynecol</source><year>1993</year><volume>168</volume><issue>3 Pt 1</issue><fpage>974</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8456911</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallak</surname><given-names>M</given-names></name></person-group><article-title>Effect of parenteral magnesium sulfate administration on excitatory amino acid receptors in the rat brain</article-title><source> Magnes Res</source><year>1998</year><volume>11</volume><issue>2</issue><fpage>117</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">9675756</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dommisse</surname><given-names>J</given-names></name></person-group><article-title>Phenytoin sodium and magnesium sulphate in the management of eclampsia</article-title><source> Br J Obstet Gynaecol</source><year>1990</year><volume>97</volume><issue>2</issue><fpage>104</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2317464</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>JM</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Creasy</surname><given-names>RK</given-names></name><name><surname>Resnik</surname><given-names>R</given-names></name></person-group><article-title>Pregnancy related hypertension</article-title><source> Maternal fetal medicine</source><year>1998</year><edition>4th ed. </edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>WB Saunders</publisher-name><fpage>833</fpage><lpage>72</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szal</surname><given-names>SE</given-names></name><name><surname>Croughan-Minihane</surname><given-names>MS</given-names></name><name><surname>Kilpatrick</surname><given-names>SJ</given-names></name></person-group><article-title>Effect of magnesium prophylaxis and preeclampsia on the duration oflabor</article-title><source> Am J Obstet Gynecol</source><year>1999</year><volume>180</volume><issue>6 Pt 1</issue><fpage>1475</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10368493</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belfort</surname><given-names>MA</given-names></name><name><surname>Clark</surname><given-names>SL</given-names></name><name><surname>Sibai</surname><given-names>B</given-names></name></person-group><article-title>Cerebral hemodynamics in preeclampsia: cerebral perfusion and the rationale for an alternative to magnesium sulfate</article-title><source> Obstet Gynecol Surv</source><year>2006</year><volume>61</volume><issue>10</issue><fpage>655</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">16978425</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>MJ</given-names></name><name><surname>Leveno</surname><given-names>KJ</given-names></name><name><surname>Cunningham</surname><given-names>FG</given-names></name></person-group><article-title>A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia</article-title><source> N Engl J Med</source><year>1995</year><volume>333</volume><issue>4</issue><fpage>201</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7791836</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slater</surname><given-names>RM</given-names></name><name><surname>Wilcox</surname><given-names>FL</given-names></name><name><surname>Smith</surname><given-names>WD</given-names></name><name><surname>Donnai</surname><given-names>P</given-names></name><name><surname>Patrick</surname><given-names>J</given-names></name><name><surname>Richardson</surname><given-names>T</given-names></name><etal/></person-group><article-title>Phenytoin infusion in severe pre-eclampsia</article-title><source> Lancet</source><year>1987</year><volume>1</volume><issue>8547</issue><fpage>1417</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">2884504</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>SC</given-names></name><name><surname>Redfern</surname><given-names>N</given-names></name><name><surname>Seviour</surname><given-names>J</given-names></name><name><surname>Campbell</surname><given-names>M</given-names></name><name><surname>Walkinshaw</surname><given-names>S</given-names></name><name><surname>Rodeck</surname><given-names>C</given-names></name><etal/></person-group><article-title>Phenytoin prophylaxis in severe pre-eclampsia and eclampsia</article-title><source> Br J Obstet Gynaecol</source><year>1993</year><volume>100</volume><issue>7</issue><fpage>623</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8369243</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appleton</surname><given-names>MP</given-names></name><name><surname>Kuehl</surname><given-names>TJ</given-names></name><name><surname>Raebel</surname><given-names>MA</given-names></name><name><surname>Adams</surname><given-names>HR</given-names></name><name><surname>Knight</surname><given-names>AB</given-names></name><name><surname>Gold</surname><given-names>WR</given-names></name></person-group><article-title>Magnesium sulfate versus phenytoin for seizure prophylaxis in pregnancy-induced hypertension</article-title><source> Am J Obstet Gynecol</source><year>1991</year><volume>165</volume><issue>4 Pt 1</issue><fpage>907</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">1951552</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unnikrishnan</surname><given-names>B</given-names></name><name><surname>Rakshith</surname><given-names>P</given-names></name><name><surname>Aishwarya</surname><given-names>A</given-names></name><name><surname>Nithin</surname><given-names>K</given-names></name><name><surname>Rekha</surname><given-names>T</given-names></name><name><surname>Prasanna</surname><given-names>P</given-names></name><etal/></person-group><article-title>Trends and Indications for cesarean Section in a tertiary care Obstetric Hospital in Coastal South India</article-title><source> Australas Med J</source><year>2010</year><volume>3</volume><issue>12</issue><fpage>821</fpage><lpage>5</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyman</surname><given-names>L</given-names></name></person-group><article-title>Is the high cesarean section rate a couse for concern?</article-title><source> Obstetrics and Gynaecology Forum</source><year>2002</year><volume>12</volume><issue>2</issue><fpage>8</fpage><lpage>13</lpage></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belfort</surname><given-names>MA</given-names></name><name><surname>Anthony</surname><given-names>J</given-names></name><name><surname>Saade</surname><given-names>GR</given-names></name><name><surname>Allen</surname><given-names>JC Jr</given-names></name></person-group><article-title>A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia</article-title><source> N Engl J Med</source><year>2003</year><volume>348</volume><issue>4</issue><fpage>304</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">12540643</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>MW</given-names></name><name><surname>Guinn</surname><given-names>D</given-names></name><name><surname>Owen</surname><given-names>J</given-names></name><name><surname>Hauth</surname><given-names>JC</given-names></name></person-group><article-title>Does magnesium sulfate affect the length oflabor induction in women with pregnancy-associated hypertension?</article-title><source> Am J Obstet Gynecol</source><year>1995</year><volume>173</volume><issue>4</issue><fpage>1219</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">7485324</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leveno</surname><given-names>KJ</given-names></name><name><surname>Alexander</surname><given-names>JM</given-names></name><name><surname>McIntire</surname><given-names>DD</given-names></name><name><surname>Lucas</surname><given-names>MJ</given-names></name></person-group><article-title>Does magnesium sulfate given for prevention of eclampsia affect the outcome oflabor?</article-title><source> Am J Obstet Gynecol</source><year>1998</year><volume>178</volume><issue>4</issue><fpage>707</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">9579432</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witlin</surname><given-names>AG</given-names></name><name><surname>Sibai</surname><given-names>BM</given-names></name></person-group><article-title>Magnesium sulfate therapy in preeclampsia and eclampsia</article-title><source> Obstet Gynecol</source><year>1998</year><volume>92</volume><issue>5</issue><fpage>883</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9794688</pub-id></element-citation></ref></ref-list></back></article>